Abstract
The primary objective of phase I oncology trials is to identify the maximum tolerated dose (MTD) of an investigational drug to inform the dose to be investigated in subsequent phases of development. This chapter review several novel phase I designs for oncology, including the continual reassessment method (CRM), modified toxicity probability interval design (mTPI), Keyboard design, and Bayesian optimal interval design (BOIN). Characteristics of these designs are explained and contrasted. Unique challenges of using phase I trials for immunotherapies and targeted therapies are described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Babb, J., Rogatko, A., & Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine, 17(10), 1103–1120.
Braun, T. M. (2002). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials, 23(3), 240–256.
Cheung, Y. K., & Chappell, R. (2000). Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics, 56(4), 1177–1182.
Cheung, Y. K. (2011). Dose finding by the continual reassessment method. CRC Press.
Guo, W., Wang, S. J., Yang, S., Lynn, H., & Ji, Y. (2017). A Bayesian interval dose-finding design addressing Ockham’s razor: mTPI-2. Contemporary Clinical Trials, 58, 23–33.
Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials, 7(6), 653–663.
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017). Is autoimmunity the Achilles’ heel of cancer immunotherapy. Nature Medicine, 23, 540–547.
Liu, S., Yin, G., & Yuan, Y. (2013). Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. The Annals of Applied Statistics, 7(4), 1837.
Liu, S., & Yuan, Y. (2015). Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C: Applied Statistics, 507–523.
Mu, R., Yuan, Y., Xu, J., Mandrekar, S. J., & Yin, J. (2019). gBOIN: A unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points. Journal of the Royal Statistical Society: Series C (Applied Statistics), 68(2), 289–308.
O’Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics, 33–48.
Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D., & Adamson, P. C. (2008). Shortening the timeline of pediatric phase I trials: The rolling six design. Journal of Clinical Oncology, 26(2), 190–195.
Pan, H., Lin, R., Zhou, Y., & Yuan, Y. (2020). Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials, 92, 105972.
Park, M., Liu, S., Yap, T. A., & Yuan, Y. (2021). Evaluation of deviation from planned cohort size and operating characteristics of phase 1 trials. JAMA Network Open, 4(2), e2037563–e2037563.
Postel-Vinay, S., Gomez-Roca, C., Molife, L. R., Anghan, B., Levy, A., Judson, I., & Paoletti, X. (2011). Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities. Journal of Clinical Oncology, 29(13), 1728–1735.
Wei, L. J. (1978). The adaptive biased coin design for sequential experiments. The Annals of Statistics, 6(1), 92–100.
Wages, N. A., Conaway, M. R., & O’Quigley, J. (2011). Continual reassessment method for partial ordering. Biometrics, 67(4), 1555–1563.
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015). Toxicities of immunotherapy for the practitioner. Journal of Clinical Oncology, 33, 2092–2099.
Yan, F., Mandrekar, S. J., & Yuan, Y. (2017). Keyboard: A novel Bayesian toxicity probability interval design for phase I clinical trials. Clinical Cancer Research, 23(15), 3994–4003.
Yin, G., & Yuan, Y. (2009). Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association, 104(487), 954–968.
Yuan, Y., Lin, R., Li, D., Nie, L., & Warren, K. E. (2018). Time-to-event Bayesian optimal interval design to accelerate phase I trials. Clinical Cancer Research, 24(20), 4921–4930.
Yuan, Y., Lin, R., & Lee, J. J. (2022). Model-assisted Bayesian designs for dose finding and optimization. Boca Raton, FL: Chapman and Hall/CRC.
Yuan, Y., Lee, J. J., & Hilsenbeck, S. G. (2019). Model-assisted designs for early-phase clinical trials: Simplicity meets superiority. JCO Precision Oncology, 3, 1–12.
Yuan, Y., & Yin, G. (2011). Robust EM continual reassessment method in oncology dose finding. Journal of the American Statistical Association, 106(495), 818–831.
Zhao, L., Lee, J., Mody, R., & Braun, T. M. (2011). The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology phase I trials. Clinical Trials, 8(4), 361–369.
Zhou, Y., Lin, R., Kuo, Y. W., Lee, J. J., & Yuan, Y. (2021). BOIN suite: A software platform to design and implement novel early-phase clinical trials. JCO Clinical Cancer Informatics, 5, 91–101.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pan, H., Yuan, Y. (2023). Introduction to Phase I Dose-Finding Clinical Trials. In: Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-19-8176-0_1
Download citation
DOI: https://doi.org/10.1007/978-981-19-8176-0_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-8174-6
Online ISBN: 978-981-19-8176-0
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)